Oglemilast is a potent PDE4 inhibitor, under clinical studies in the treatment of allergen-induced asthma.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | PDE ↓ ↑ | PDE1 ↓ ↑ | PDE10A ↓ ↑ | PDE2 ↓ ↑ | PDE3 ↓ ↑ | PDE4 ↓ ↑ | PDE5 ↓ ↑ | PDE6 ↓ ↑ | 其他靶点 | 纯度 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Doxofylline | ✔ | 99+% | |||||||||||||||||
Deltarasin |
+++
PDEδ , Kd: 38 nM |
96% | |||||||||||||||||
7-(2,3-Dihydroxypropyl)theophylline | ✔ | 98% | |||||||||||||||||
Aminophylline |
+
PDE, IC50: 0.12 mM |
98+% | |||||||||||||||||
Anagrelide HCl | ✔ | 99%+ | |||||||||||||||||
Irsogladine | ✔ | mAChR,AChR | 99% | ||||||||||||||||
PF-8380 |
+++
Autotaxin, IC50: 2.8 nM |
99%+ | |||||||||||||||||
Dipyridamole | ✔ | 98% | |||||||||||||||||
Luteolin |
+
PDE1, Ki: 15.0 μM |
++
PDE2, Ki: 6.4 μM |
+
PDE3, Ki: 13.9 μM |
+
PDE4, Ki: 11.1 μM |
+
PDE5, Ki: 9.5 μM |
98% | |||||||||||||
Balipodect |
++++
PDE10A, IC50: 0.3 nM |
99%+ | |||||||||||||||||
PF-2545920 |
++++
PDE10A, IC50: 0.37 nM |
97% | |||||||||||||||||
Milrinone |
++
PDE2, IC50: 5.2 μM |
++
PDE3, IC50: 2.1 μM |
ATPase | 99% | |||||||||||||||
Pimobendan |
++
PDE3, IC50: 0.32 μM |
98% | |||||||||||||||||
Cilostazol |
++
PDE3, IC50: 0.2 μM |
98% | |||||||||||||||||
(S)-(+)-Rolipram |
++
PDE4, IC50: 0.75 μM |
99% (HPLC) | |||||||||||||||||
Apremilast |
+++
PDE4, IC50: 74 nM |
98% | |||||||||||||||||
GSK256066 |
++++
PDE4B, IC50: 3.2 pM |
98+% | |||||||||||||||||
Roflumilast |
++++
PDE4A4, IC50: 4.3 nM PDE4A1, IC50: 0.7 nM |
99% | |||||||||||||||||
Rolipram |
+++
PDE4B, IC50: 130 nM |
99%+ | |||||||||||||||||
Cilomilast |
+++
HPDE4, IC50: 120 nM LPDE4, IC50: 100 nM |
99% | |||||||||||||||||
Fenspiride HCl |
+
PDE3, pIC50: 3.44 |
+
PDE4, pIC50: 4.16 |
99% (HPLC) | ||||||||||||||||
Avanafil |
++++
PDE5, IC50: 1 nM |
98% | |||||||||||||||||
Vardenafil HCl Trihydrate |
++++
PDE5, IC50: 0.7 nM |
98% | |||||||||||||||||
Tadalafil |
++++
PDE5, IC50: 1.8 nM |
98% | |||||||||||||||||
Icariin |
++
PDE5, IC50: 0.432 μM |
98% | |||||||||||||||||
Sildenafil | ✔ |
+++
PDE6, IC50: 33 nM |
98% | ||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | Oglemilast, identified as GRC 3886, is a highly effective and orally available inhibitor of phosphodiesterase-4 (PDE4), with an IC50 value of 0.5 nM for PDE4D3. It is effective in reducing pulmonary cell infiltration, such as eosinophilia and neutrophilia, both in vitro and in vivo, showing potential as a treatment for inflammatory airway conditions[1][2][3]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00671073 | Pulmonary Disease, Chronic Obs... 展开 >>tructive 收起 << | Phase 2 | Completed | - | - |
NCT00859404 | Asthma | Phase 2 | Unknown | January 2010 | India ... 展开 >> Glenmark investigational sites (28) Mumbai, Bangalore etc, India 收起 << |
NCT00322686 | Asthma | Phase 2 | Completed | - | United States, California ... 展开 >> Forest Investigative Site Los Angeles, California, United States, 90025 收起 << |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.94mL 0.39mL 0.19mL |
9.68mL 1.94mL 0.97mL |
19.37mL 3.87mL 1.94mL |
CAS号 | 778576-62-8 |
分子式 | C20H13Cl2F2N3O5S |
分子量 | 516.3 |
SMILES Code | O=C(C1=C2C(OC3=CC=C(NS(=O)(C)=O)C=C23)=C(OC(F)F)C=C1)NC4=C(Cl)C=NC=C4Cl |
MDL No. | MFCD18633298 |
别名 | GRC 3886 |
运输 | 蓝冰 |
InChI Key | OKFDRAHPFKMAJH-UHFFFAOYSA-N |
Pubchem ID | 11387409 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Inert atmosphere, store in freezer, under -20°C |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|